Addex

Allosteric modulators for human health

  • About us
    • Addex Corporate Presentation
    • Overview
    • Our people
      • Executive Officers
      • Non-Executive Directors
      • Scientific Advisory Board
    • Contact
    • Privacy Policy
    • Careers
  • Pipeline
    • Clinical and Pre-Clinical Pipeline
    • Research And Development
  • Technology platform
    • Allosteric modulation
    • Our capabilities
      • Screening Assays
      • Chemistry
    • Publications
  • Partners & collaboration
  • Investors
    • Addex Corporate Presentation
    • Stock Data
    • Press releases
    • Ad hoc announcements (Art. 53 L.R)
    • Events
    • Financial Reports
    • Analyst Reports
    • General Meetings
    • SEC / SIX Filings
    • Guide to US ADSS for Six Shareholders
    • Register for email news
    • Corporate Governance
    • Contact
  • Media
    • Press releases
    • Contact
about us

about us

Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders.

Pipeline

Clinical and Pre-Clinical Pipeline

 

 

 

Research And Development

   

 

Publications
  • Dipraglurant-IR for PD-LID
  • ADX71149 for epilepsy
  • GABAB PAM for the treatment of substance use disorder
  • GABAB PAM for the treatment of pain and CMT1A
  • mGlu7 NAM for PTSD
  • mGlu2 NAM for mild neurocognitive disorders
  • M4 PAM for Schizophrenia & Other Psychosis
  • mGlu4 PAM for Parkinson’s disease
  • mGlu3 PAM for neurodegenerative disorders
Placeholder image

Technology platform

Allosteric Modulation

Read more
Placeholder image

Partners & Collaborations

Industry

Read more

Latest news Latest news icon

  • 07.26
    2022

    Addex Completes $4.2 Million Equity Financing

  • 07.22
    2022

    Addex Raises $4.2 million in Equity Financing

  • 07.21
    2022

    Addex Provides Corporate Update and Financial Guidance

  • 07.21
    2022

    Addex Completes Reduction in Nominal Value of Shares

  • 06.17
    2022

    Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate

Contact us

If you have any questions please let me know
  • Contact form
2022 © Addex therapeutics